cerelume

Brain tumour liquid biopsy

Reading the brain through blood.

Cerelume is developing MethyGlio, a liquid biopsy that detects glioma and identifies its molecular class through cell-free DNA (cfDNA) methylation, enabling earlier diagnosis, ongoing monitoring and treatment decisions without waiting for surgery.

Explore our science Meet the founders

Research-stage platform · Not yet commercially available

Atlas data provenance

74 datasets · 8 countries · 25,750 methylation arrays

Hover or tap a country for its centres

BethesdaDetroitMinneapolisNew HavenBaltimoreHeidelbergHamburgMunichBerlinErlangenNewcastle upon TyneHinxtonTorontoYokohamaTokyoMadridEsplugues de LlobregatBeijingParisUnited States13,029 arraysCanada888 arraysUnited Kingdom2,957 arraysFrance24 arraysSpain86 arraysGermany8,546 arraysChina46 arraysJapan174 arrays

Methylation arrays per country

  • under 100
  • 100 to 999
  • 1,000 to 9,999
  • 10,000 or more
  • no dataset
  • centre city

Atlas built from public methylation datasets; hover a country for the contributing centres.3

15,606

harmonised methylation profiles in the atlas1

99.2%

glioma subtype accuracy, leakage-controlled1

0.90 to 0.96

AUC in a prospective cohort of 68 patients (data on file)1

<50%

of primary brain tumours shed detectable tumour DNA into blood2

Explore Cerelume

A clearer answer, without relying on another operation.

Our science

The problem, and MethyGlio

Diagnosis waits for surgery, tracking progression and drug resistance means repeat operations, and patients who cannot be operated on are treated without a specific diagnosis. MethyGlio is a liquid biopsy built to diagnose without surgery and monitor disease progress over time, for earlier intervention and better outcomes.

Read more

Evidence

Presented at ESMO and MAP

The MethyGlio liquid biopsy work has been presented as oral presentations at ESMO and MAP, and the manuscript is under journal review. The peer-reviewed glioma papers it builds on are listed too.

Read more

Platform

From blood sample to result

AI identifies the specific methylation biomarkers that survive in blood, which is what makes a glioma liquid biopsy real: a targeted assay, a hierarchical read and an interpretable report.

Read more

Company

Founders and who we serve

A neurosurgeon-scientist and a physician-founder, building for clinical teams, trial sponsors and researchers.

Read more

Collaborate with Cerelume

Help bring a clearer signal to brain tumour care.

Start a conversation

References

  1. 1Maimaiti A, et al. MethyGlio: cfDNA methylation and liquid biopsy for glioma classification. Manuscript under journal review. Data on file, Cerelume; 2026.
  2. 2Bettegowda C, et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med. 2014;6. doi:10.1126/scitranslmed.3007094
  3. 3Public methylation datasets from the NCBI Gene Expression Omnibus and The Cancer Genome Atlas (GDC Data Portal), and the MeLB serum cfDNA set (Mendeley Data). Accessions are listed in the MethyGlio manuscript. doi:10.17632/zrc982rvjm.2